Late Thursday, federal regulators released a redacted 121-page inspection report of a Newark, California Theranos facility, which revealed that the company’s high-profile finger-prick blood tests failed quality control checks nearly 30 percent of the time.

Theranos and its CEO, Elizabeth Holmes, made waves last year with claims that they could carry out more than 200 medical tests with their Edison devices using just a few drops of blood from a finger prick—rather than a full vein draw taken by a needle. With promises that the cheap and easy finger-prick tests could revolutionize medical diagnostics, the company was valued at $9 billion.

However, since the initial buzz, the company has been hit with a series of questions, criticisms, and federal regulatory snags surrounding the accuracy and validity of its tests. In the latest setback, the Centers for Medicare and Medicaid Services (CMS) released a redacted inspection report that seems to substantiate concerns and whistleblower reports of the Edison’s failings.

The report, reviewed in full by the Wall Street Journal, revealed that in early 2015, Edison-based tests for a hormone related to testosterone levels failed quality-control checks 87 percent of the time. A test to help detect prostate cancer (measuring prostate-specific antigen, PSA) failed 22 percent of the time. In October 2014, Edison-run tests for the hormone Prolactin failed 47 percent of the time.

Inspectors also noted that the quality control results were often erratic, test results were sometimes wildly different from results produced by standard lab devices, unqualified employees ran some tests, and the company failed to update doctors about quality control issues in a timely manner—in some cases taking seven weeks.

The performance of the Edison devices even failed internal standards set by the company. For instance, Theranos procedures state that the difference between an Edison’s measurement of Vitamin D in a blood sample should be equal to or less than 20 percent different from the same blood sample’s Vitamin D level measured by a traditional machine. But in the inspection, differences on nine randomly selected blood samples ranged from 21 percent to 130 percent.

“This is the first time that we’ve actually seen data from the Theranos instrument, and it’s as bad as one would have worried it would be,” Stephen Master, a pathology professor at Weill Cornell Medical College told the WSJ. “Based on this data, it’s hard for me to believe that they went live with this instrument and tested patient specimens on it.”

In a statement on its website, Theranos spokesperson Brooke Buchanan wrote that the company has “proactively” suspended some testing and is working with the CMS to address all of the problems. “We’ve made mistakes in the past in the Newark, CA lab, but when the company was made aware of the deficiencies, we have dedicated every resource to remedy those failures,” Buchanan wrote.

But the WSJ reports that the CMS is unsatisfied with the company’s plan and intends to impose sanctions that could range from fines to a retraction of the company’s approval to test human samples.